http://www.nature.com/aps/journal/v30/n6/full/aps200937a.html Excerpt: In addition, selective nicotinic ligands that affect the pro-inflammatory pathway from the transcriptional level upward provide a new therapeutic class possessing a potentially better mechanism of action for the treatment of inflammatory and autoimmune disorders. These ligands achieve this by modulating a broad array of cytokines and cellular pathways that are involved in cell homeostasis, an effect that would not be possible by targeting individual proteins. The mechanistic overlap between the signaling pathways involved in neuroprotective mechanisms and in controlling inflammation may provide the tools needed to control and break the vicious cycle of cell death and inflammation. The aptly named Janus kinase, the deity of gateways, beginnings, and endings in roman mythology, resides at the crossroad of these bimodal signaling cascades and may provide a convenient target via NNR modulation for novel therapies designed to manage the disruption of regulatory proteins that are central to cellular homeostasis. The present therapeutic armamentarium is lacking drugs directed toward some of the fundamental pathways involved in cell survival and chronic inflammation that have been increasingly implicated in some of the most devastating diseases, including atherosclerosis, diabetes, neurodegenerative diseases, chronic obstructive pulmonary diseases, inflammatory bowel diseases, and other untractable diseases. The potential to target neuronal survival and chronic inflammation could be a turning point in our ability to manage some of the most costly public health issues of our time. Although there is mounting evidence for the potential of NNRs to target the hallmark of diseases that may constitute the biggest public health challenges, the regulatory path for such therapies remains to be established and only global pharmaceutical companies with a strategic interest in these areas have the means to undertake the task of extended clinical trials and to influence the regulatory bodies to pave the way for such new therapies.